A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult Patients With Bullous Pemphigoid
第2/3相
完了
NCT04206553
| 対象疾患 | Bullous Pemphigoid |
|---|
| 相 | 第2/3相 |
|---|
| スポンサー | Regeneron Pharmaceuticals |
|---|
| ステータス | 完了 |
|---|
| 参加者数 | 106 名 |
|---|
| 介入（薬剤） | dupilumab, Matching Placebo, Oral corticosteroids (OCS) |
|---|
| 開始日 | 2020年10月28日 |
|---|
| 完了日 | 2024年7月12日 |
|---|
| 結果公開日 | 2026年3月6日 |
|---|
概要
The main purpose of this study is to investigate whether dupilumab is effective and safe for the treatment of bullous pemphigoid. Dupilumab is a type of drug called a "monoclonal antibody". An antibody is a special kind of protein that the immune (defense) system normally makes to fight bacteria and viruses. Bullous pemphigoid is an autoimmune subepidermal blistering disease, predominately affecting the elderly (typical onset after age 60). The study is looking at several other research questions, including: * Side effects that may be experienced by people taking dupilumab * How dupilumab works in the body and affects the body * How dupilumab affects quality of life * How much dupilumab is present in the blood * To see if dupilumab works to wean the patient off oral corticosteroids
Percent of Participants Achieving Sustained Remission at Week 36
At Week 36 · Estimated Percentage of Participants
| Placebo | 4.0 Estimated Percentage of Participants |
|---|
| Dupilumab Q2W | 18.2 Estimated Percentage of Participants |
|---|
| p-value | 0.0250 |
|---|
| Risk Difference (RD) | 14.2 (95% CI 1.97–27.74) |
|---|
BENITIONS で見る
ClinicalTrials.gov の原文を見る
すべての治験
このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。